Infogene is a spin-off of two researchers linked to the Portuguese Institute of Oncology of Coimbra (IPO), the Faculty of Medicine of the University of Porto and the Faculty of Medicine of the University of Coimbra, that taking into consideration its own R&D activities, identified several business opportunities related to the applications of genetics in the screening, early detection, diagnosis and treatment of cancer. Its evolution is following the direction of opting strongly for R&D, establishing strategic partners and commercial exploration of R&D activities through the development of sensitive and non-invasive diagnostic devices. Infogene launched an innovative diagnostic test product for human papilloma and for colorectal and uterine cancer.

The investigation of biomarkers in biological fluids of cancer patients as a way to develop non-invasive methods of early detection is a strategic point of the company. This is complemented by the conception of new medical devices for the collection of biological samples. In this framework, its business strategy is aimed at diversifying its product catalog, covering solutions for the most prevalent types of cancer. Therefore, Infogene is interested in participating in this project in the context of conducting molecular analyzes for the tracking of monoclonal B lymphocytosis and the development of innovative medical devices and molecular analyzes for the early non-invasive screening of chronic lymphocytic leukemia.